NASDAQ:LPCN - Lipocine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.22 +0.03 (+2.52 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.22
Today's Range$1.20 - $1.22
52-Week Range$1.03 - $5.33
Volume69,274 shs
Average Volume496,966 shs
Market Capitalization$26.37 million
P/E Ratio-1.16
Dividend YieldN/A
Beta0.52

About Lipocine (NASDAQ:LPCN)

Lipocine logoLipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383

Debt

Debt-to-Equity Ratio0.52
Current Ratio5.03
Quick Ratio5.04

Price-To-Earnings

Trailing P/E Ratio-1.16
Forward P/E Ratio-1.33
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.78 per share
Price / Book1.56

Profitability

EPS (Most Recent Fiscal Year)($1.05)
Net Income$-20,980,000.00
Net MarginsN/A
Return on Equity-89.14%
Return on Assets-67.72%

Miscellaneous

Employees14
Outstanding Shares21,260,000

Lipocine (NASDAQ:LPCN) Frequently Asked Questions

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine (NASDAQ:LPCN) released its quarterly earnings results on Monday, May, 7th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.08. The specialty pharmaceutical company had revenue of $0.43 million for the quarter. View Lipocine's Earnings History.

When is Lipocine's next earnings date?

Lipocine is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Lipocine.

What price target have analysts set for LPCN?

5 brokerages have issued 1-year price targets for Lipocine's shares. Their predictions range from $2.00 to $38.00. On average, they expect Lipocine's stock price to reach $12.80 in the next year. View Analyst Ratings for Lipocine.

Who are some of Lipocine's key competitors?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:
  • Dr. Mahesh V. Patel Ph.D., Co-Founder, Chairman, Pres & CEO (Age 61)
  • Mr. Morgan R. Brown MBA, CPA, Exec. VP, CFO & Corp. Sec. (Age 50)
  • Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 87)
  • Dr. Anthony DelConte M. D., Chief Medical Director (Age 60)
  • Mr. Gregory B. Bass, Exec. VP & Chief Commercial Officer (Age 44)

Has Lipocine been receiving favorable news coverage?

News coverage about LPCN stock has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lipocine earned a news impact score of 0.18 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 47.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $1.22.

How big of a company is Lipocine?

Lipocine has a market capitalization of $26.37 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]


MarketBeat Community Rating for Lipocine (LPCN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Lipocine (NASDAQ:LPCN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Lipocine in the last 12 months. Their average twelve-month price target is $12.80, suggesting that the stock has a possible upside of 949.18%. The high price target for LPCN is $38.00 and the low price target for LPCN is $2.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.753.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.80$12.80$13.50$24.6667
Price Target Upside: 949.18% upside776.71% upside621.93% upside470.99% upside

Lipocine (NASDAQ:LPCN) Consensus Price Target History

Price Target History for Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ:LPCN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightSet Price TargetBuy$3.00MediumView Rating Details
3/29/2018Seaport Global SecuritiesInitiated CoverageBuy$10.00MediumView Rating Details
3/13/2018Canaccord GenuityReiterated RatingHold$2.00MediumView Rating Details
1/11/2018Ladenburg ThalmannReiterated RatingBuy$11.00HighView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$38.00MediumView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Lipocine (NASDAQ:LPCN) Earnings History and Estimates Chart

Earnings by Quarter for Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ:LPCN) Earnings Estimates

2018 EPS Consensus Estimate: $0.00
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.82$0.82$0.82
Q2 20183($0.32)($0.21)($0.25)
Q3 20183($0.35)($0.22)($0.28)
Q4 20183($0.39)($0.23)($0.30)

Lipocine (NASDAQ LPCN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/7/2018Q1 2018($0.2120)($0.1280)$0.43 millionViewN/AView Earnings Details
3/12/2018Q4 2017($0.21)($0.2510)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.27)($0.22)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.2970)($0.31)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.30)($0.26)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.28)($0.16)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.30)($0.16)ViewN/AView Earnings Details
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.29)($0.25)ViewN/AView Earnings Details
11/12/2015Q3($0.3450)($0.35)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.42)($0.55)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.35)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Lipocine (NASDAQ:LPCN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Lipocine (NASDAQ LPCN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 9.71%
Insider Trading History for Lipocine (NASDAQ:LPCN)
Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ LPCN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2017Gregory Brooks BassInsiderSell3,750$3.47$13,012.50View SEC Filing  
12/29/2017Gregory Brooks BassInsiderSell3,750$3.47$13,012.509,375View SEC Filing  
12/29/2017Jeffrey Arvin FinkDirectorSell938$3.47$3,254.86View SEC Filing  
12/29/2017Mahesh V PatelCEOSell6,000$3.48$20,880.00View SEC Filing  
12/29/2017Mahesh V PatelCEOSell6,000$3.48$20,880.00728,112View SEC Filing  
12/29/2017Morgan R BrownCFOSell2,813$3.47$9,761.1126,375View SEC Filing  
12/29/2017Morgan R BrownCFOSell2,813$3.47$9,761.11View SEC Filing  
12/29/2017Stephen A HillDirectorSell1,250$3.47$4,337.506,500View SEC Filing  
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00693,382View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00887,632View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Lipocine (NASDAQ LPCN) News Headlines

Source:
DateHeadline
-$0.26 Earnings Per Share Expected for Lipocine (LPCN) This Quarter-$0.26 Earnings Per Share Expected for Lipocine (LPCN) This Quarter
www.americanbankingnews.com - May 20 at 9:06 PM
Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)
finance.yahoo.com - May 17 at 8:22 AM
LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA ResponseLPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response
finance.yahoo.com - May 14 at 5:20 PM
Lipocine to Post Q3 2018 Earnings of ($0.22) Per Share, Zacks Investment Research Forecasts (LPCN)Lipocine to Post Q3 2018 Earnings of ($0.22) Per Share, Zacks Investment Research Forecasts (LPCN)
www.americanbankingnews.com - May 14 at 3:06 AM
Lipocine (LPCN) Receives Average Recommendation of "Buy" from BrokeragesLipocine (LPCN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 9:49 AM
Lipocine Expected to Post Q2 2018 Earnings of ($0.22) Per Share (LPCN)Lipocine Expected to Post Q2 2018 Earnings of ($0.22) Per Share (LPCN)
www.americanbankingnews.com - May 11 at 8:35 AM
HC Wainwright Analysts Give Lipocine (LPCN) a $3.00 Price TargetHC Wainwright Analysts Give Lipocine (LPCN) a $3.00 Price Target
www.americanbankingnews.com - May 10 at 7:05 PM
Seaport Global Securities Analysts Lower Earnings Estimates for Lipocine (LPCN)Seaport Global Securities Analysts Lower Earnings Estimates for Lipocine (LPCN)
www.americanbankingnews.com - May 10 at 6:51 AM
BRIEF-Lipocine Receives Complete Response Letter For Tlando From US FDABRIEF-Lipocine Receives Complete Response Letter For Tlando From US FDA
www.reuters.com - May 9 at 5:33 PM
Lipocines Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock TanksLipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks
feeds.benzinga.com - May 9 at 11:17 AM
Seaport Global Securities Analysts Cut Earnings Estimates for Lipocine (LPCN)Seaport Global Securities Analysts Cut Earnings Estimates for Lipocine (LPCN)
www.americanbankingnews.com - May 9 at 9:47 AM
Lipocine (LPCN) Receives CRL for TLANDO From FDALipocine (LPCN) Receives CRL for TLANDO From FDA
www.streetinsider.com - May 9 at 8:19 AM
Lipocine shares drop 38% after FDA fails to approve testosterone replacement therapyLipocine shares drop 38% after FDA fails to approve testosterone replacement therapy
finance.yahoo.com - May 9 at 8:19 AM
Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug AdministrationLipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration
finance.yahoo.com - May 9 at 8:19 AM
Lipocine (LPCN) Upgraded to "Sell" by ValuEngineLipocine (LPCN) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - May 8 at 11:26 PM
Lipocine (LPCN) Announces Quarterly  Earnings Results, Beats Expectations By $0.08 EPSLipocine (LPCN) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 8 at 12:44 PM
Benzingas Daily Biotech Pulse: Valeant Earnings, Lipocines FDA Watch, Invivo CFO DepartureBenzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure
www.benzinga.com - May 8 at 8:16 AM
BRIEF-Lipocine Announces Q1 Loss Per Share $0.13BRIEF-Lipocine Announces Q1 Loss Per Share $0.13
www.reuters.com - May 7 at 5:38 PM
Lipocine: 1Q Earnings SnapshotLipocine: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:38 PM
Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018
finance.yahoo.com - May 7 at 8:20 AM
Form DEFA14A Lipocine Inc.Form DEFA14A Lipocine Inc.
www.streetinsider.com - May 4 at 8:18 AM
Lipocine (LPCN) Expected to Announce Earnings of -$0.19 Per ShareLipocine (LPCN) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 3 at 6:10 PM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc ...Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc ...
globenewswire.com - April 23 at 8:15 AM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCNPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCN
finance.yahoo.com - April 23 at 8:15 AM
Lipocine (LPCN) Receives Average Recommendation of "Buy" from AnalystsLipocine (LPCN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 8:40 AM
Lipocine (LPCN) Downgraded to "Sell" at ValuEngineLipocine (LPCN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM
Roth Capital Analysts Give Lipocine (LPCN) a $38.00 Price TargetRoth Capital Analysts Give Lipocine (LPCN) a $38.00 Price Target
www.americanbankingnews.com - April 10 at 8:23 PM
LPCN: Coming at the FDA Like a Spider MonkeyLPCN: Coming at the FDA Like a Spider Monkey
finance.yahoo.com - April 2 at 5:27 PM
Canaccord Genuity Reaffirms "Hold" Rating for Lipocine (LPCN)Canaccord Genuity Reaffirms "Hold" Rating for Lipocine (LPCN)
www.americanbankingnews.com - March 29 at 9:04 PM
Seaport Global Securities Initiates Coverage on Lipocine (LPCN)Seaport Global Securities Initiates Coverage on Lipocine (LPCN)
www.americanbankingnews.com - March 29 at 12:28 PM
Lipocine (LPCN) Stock Rating Lowered by Canaccord GenuityLipocine (LPCN) Stock Rating Lowered by Canaccord Genuity
www.americanbankingnews.com - March 28 at 11:32 PM
Lipocine Inc (LPCN) Given Consensus Recommendation of "Hold" by BrokeragesLipocine Inc (LPCN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 8:04 AM
Lipocine to Present at the 17th Annual Needham Healthcare ConferenceLipocine to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:49 AM
Lipocine to Present at the Oppenheimer 28th Annual Healthcare ConferenceLipocine to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:33 AM
Lipocine (LPCN) Rating Reiterated by Canaccord GenuityLipocine (LPCN) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - March 13 at 6:22 PM
-$0.26 Earnings Per Share Expected for Lipocine Inc (LPCN) This Quarter-$0.26 Earnings Per Share Expected for Lipocine Inc (LPCN) This Quarter
www.americanbankingnews.com - March 13 at 12:19 PM
Lipocine (LPCN) Issues Quarterly  Earnings ResultsLipocine (LPCN) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:39 AM
Lipocine Announces Financial and Operational Results for the ... - PR Newswire (press release)Lipocine Announces Financial and Operational Results for the ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 6:39 PM
Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017
finance.yahoo.com - March 12 at 9:03 AM
Interested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks LikeInterested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - March 6 at 8:15 AM
373,101 Shares in Lipocine Inc (LPCN) Purchased by Prosight Management LP373,101 Shares in Lipocine Inc (LPCN) Purchased by Prosight Management LP
www.americanbankingnews.com - March 5 at 4:07 PM
Lipocine to Present at the 30th Annual ROTH ConferenceLipocine to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 8:18 AM
UPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, Conceivable Approval on PDUFAUPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, 'Conceivable Approval on PDUFA'
www.streetinsider.com - February 28 at 6:03 PM
UPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, Conceivable Approval on PDUFA - StreetInsider.comUPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, 'Conceivable Approval on PDUFA' - StreetInsider.com
www.streetinsider.com - February 28 at 8:18 AM
Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy RatingEmpire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating
finance.yahoo.com - February 27 at 5:54 PM
Lipocine Inc (LPCN) Receives Consensus Rating of "Hold" from AnalystsLipocine Inc (LPCN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 27 at 9:52 AM
Lipocine (LPCN) to Release Earnings on MondayLipocine (LPCN) to Release Earnings on Monday
www.americanbankingnews.com - February 26 at 3:38 AM
Lipocine Inc (LPCN) Expected to Post Earnings of -$0.26 Per ShareLipocine Inc (LPCN) Expected to Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - February 24 at 9:26 AM
LIPOCINE INVESTIGATION INITIATED BY FORMER...LIPOCINE INVESTIGATION INITIATED BY FORMER...
www.benzinga.com - February 17 at 8:14 AM
LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCNLIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN
finance.yahoo.com - February 17 at 8:14 AM

SEC Filings

Lipocine (NASDAQ:LPCN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Lipocine (NASDAQ:LPCN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Lipocine (NASDAQ LPCN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.